The patent covers the methods and compositions to treat cancer using oncolytic Respiratory Syncytial Virus or (RSV) activity.
The agreement, in conjunction with the US and worldwide patents for which CZ Biomed has already applied is expected to add to the company’s existing patent portfolio of innovative oncolytic cancer treatments.
CZ BioMed CEO Calvin Cao said the licensing agreement has been an important acquisition as it protects the precursors to the advanced work using a genetically engineered form of RSV.
”We are extremely fortunate and proud to have the UT Health Science Center at San Antonio as our partner, as we bring our proprietary Genetically Engineered RSV to the forefront of cancer treatments," Cao added.
Oncolytic virotherapy is a cancer treatment in which selected viruses are introduced to the body to infect and kill cancer cells without any adverse effects on normal healthy cells.